Therapies
Friday, February 10th, 2012
Brightsurf Science News: In the largest and longest head-to-head comparison of two anti-clotting medications, warfarin and aspirin were similar in preventing deaths and strokes in heart failure patients with normal heart rhythm, according to late-breaking research presented at the American Stroke Association’s International Stroke Conference 2012. “Although there was a warfarin benefit for patients treated for […]
Therapies
Friday, February 10th, 2012
Cardiology Today: International Stroke Conference 2012. NEW ORLEANS — One in two stroke survivors have poorly controlled hypertension and equally poor rates of antihypertensive therapy, according to data presented at the American Stroke Association’s International Stroke Conference. Amytis Towfighi, MD, and colleagues reviewed the prevalence and control of hypertension among 490 adult stroke survivors who participated in the National Health […]
Therapies
Friday, February 10th, 2012
By: Deanna Morey – Published: Feb 7, 2012 08:34 pm: (dailyRx) Technology and procedures to treat unruptured brain aneurysms, which can lead to hemorrhagic stroke caused by cranial bleeding, have improved significantly in the last decade. Treatment outcomes have not improved with the technology, however, suggesting that higher numbers of procedures performed at smaller community hospitals are […]
Therapies
Friday, February 10th, 2012
By: ALICIA AULT, Cardiology News Digital Network: NEW ORLEANS – A review of a stroke registry shows that it may be safe to give clot-busting therapy to “wake-up” stroke patients who have the same clinical and imaging features as those of patients who are traditionally considered eligible for the therapies. Clinicians have traditionally shied away from giving […]
Therapies
Friday, February 10th, 2012
By Maureen Salamon – HealthDay Reporter: WEDNESDAY, Feb. 1 (HealthDay News) — Treating stroke patients with stem cells taken from their own bone marrow appears to safely help them regain some of their lost abilities, two small new studies suggest. Indian researchers observed mixed results in the extent of stroke patients’ improvements, with one study showing marked gains in daily activities, […]
Therapies
Friday, February 10th, 2012
By Chris Kaiser, Cardiology Editor, MedPage Today: Published: February 08, 2012. Reviewed by Dori F. Zaleznik, MD; Associate Clinical Professor of Medicine, Harvard Medical School, Boston and Dorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planner NEW ORLEANS — Dabigatran (Pradaxa) is more cost-effective than warfarin at preventing stroke in atrial fibrillation patients who have had a prior stroke or transient […]
Therapies
Friday, February 10th, 2012
Beaumont-led research may reduce unnecessary procedures and cost. Royal Oak, Mich. (PRWEB) February 09, 2012 An important research study, led by Beaumont Health System cardiologists and involving 47 hospitals and outpatient centers in Michigan, may help spare patients from unnecessary invasive heart procedures while lowering health care costs. The research, published in the Feb. 14 […]
Therapies
Friday, November 11th, 2011
The Genotype Guided Dosing of Warfarin Clinical Trial, sponsored by the National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), is soliciting applications from suitable clinical research centers. The University of Pennsylvania serves as the Clinical Trial Coordinating Center (CTCC) for this study. Clinical sites will participate as a subcontract to the […]
Therapies
Friday, November 11th, 2011
JON D. HORTON, PHARM.D., and BRUCE M. BUSHWICK, M.D. York Hospital York, Pennsylvania Warfarin is the oral anticoagulant most frequently used to control and prevent thromboembolic disorders. Prescribing the dose that both avoids hemorrhagic complications and achieves sufficient suppression of thrombosis requires a thorough understanding of the drug’s unique pharmacology. Warfarin has a complex dose-response […]
Therapies
Friday, November 11th, 2011
Five More Sites to Begin Enrollment in Coming Weeks – Iverson Genetic Diagnostics said this week that the Franciscan Health System in Tacoma, Wash., has begun enrolling patients for the WARFARIN (Warfarin Adverse Event Reduction for Adults Receiving Genetic Testing at Therapy Initiation) study that the company is leading in an effort to demonstrate the utility of […]
